CClinicalTrials.gg
WithdrawnNCT04942184Updated Nov 1, 2022

STRATEGIES to Improve Memory in Alzheimer's Disease

An interventional study of Memory strategies in Arm 1 and Electroencephalogram (EEG) headset in Arm 1 in Alzheimer Disease, Dementia, Mild and Mild Cognitive Impairment, sponsored by Boston University. Withdrawn. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-11-01.

Sponsored by Boston University · Not applicable, Interventional, and Prevention

Why this study was withdrawn
Study was never started due to the Covid 19 pandemic.
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Study summary

Memory mistakes are one of the most detrimental symptoms in Alzheimer's Disease (AD). In this study the investigators will measure the long-term efficacy of memory strategies in patients with AD. First, the efficacy of the strategies will be evaluated in the laboratory by analyzing the behavioral response and the brain activity of the patients. During the first visit, patients will be taught the memory strategies and asked to repeat them at home for 4 weeks. During this period of time, patients will perform several memory tasks while their performance and brain activity will be measured using portable devices. Monitoring brain activity and behavioral responses to memory tasks will provide insightful information on the efficacy of the strategies and allow the investigation of how patients can maintain the strategies over time. The research will examine if improving memory through the use of cognitive strategies, can positively affect other domains of daily life.

Read the detailed description

A crossover design with two groups will be implemented to test the following objectives:

Primary Objective: To determine the long-term efficacy of memory strategies in AD patients using experimental memory paradigms and standard neuropsychological tests. Over the course of 4 weeks, performance on novel memory tasks and standard neuropsychological tests will evaluate the efficacy of the strategies longitudinally.

Secondary Objectives:

  1. To determine the neural mechanism of memory strategies in AD patients through portable electroencephalogram/event-related potential (EEG/ERP) electrophysiology. Portable EEG will allow us to measure the electrophysiological changes associated with the use of memory strategies over time during daily life of patients with AD.
  2. To determine how memory strategies, influence the daily life and functioning of the AD patients. Questionnaires on daily life activities will be administered at different timepoints to determine whether patients are able to generalize the strategies to tasks in their daily life.

This research study will investigate whether the use of combined memory strategies (conservative and deep/item-specific encoding) can help improve performance in memory tasks, can be maintained over time, and can be generalized to other tasks in daily life. Depending on the study group, either at week 0 visit or week 2 visit, participants will be trained on the two strategies. A power point presentation will be used to display one example of each of the strategies and how to implement them during the tablet/Ipad tasks. At this time the investigators will answer any other specific questions that might come up about the strategies. Before starting the cognitive tasks at home on the app, the tablet will remind participants about using the strategies, and this will also include an example how the strategies should be implemented.

The two memory strategies will be implemented in the described steps below:

While being presented with a list of items (words or objects), participants will be asked to focus on one unique characteristic of the items (item-specific encoding strategy). Afterwards, another list of items, containing previously studied (old) and unstudied (new) items, will be presented. Participants will be asked to recognize whether the item was presented in the previous list and respond "yes" only if they are absolutely sure of their response (conservative strategy). Participants will then be provided with a number of real-world examples to practice generalizing what they have learned.

02

Conditions studied

  • Alzheimer Disease
  • Dementia, Mild
  • Mild Cognitive Impairment

Keywords

  • Memory
  • Memory Strategies
  • EEG headgear
03

In context

Alzheimer Disease

3,678 studies on the registry are indexed under Alzheimer Disease; 872 are open to participants now.

Browse Alzheimer Disease studies →

Lead sponsor

Boston University is the lead sponsor of 266 studies on the registry; 37 are open to participants now.

Of its 30 completed or terminated interventional studies of FDA-regulated products, 24 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

For Mild Alzheimer Disease (AD) dementia

  • meets probable AD dementia National Institute on Aging and Alzheimer's Association (NIA-AA) criteria
  • Mini-Mental State Examination (MMSE) 20-27
  • performance on delayed recall and recognition memory worse than 1.5 standard deviation (SD) for age and education
  • performance on delayed recall and recognition memory worse than 1.5 SD for age \& education in at least one other cognitive domain (e.g., language, executive functioning) based on other tests in our neuropsychological test battery.
  • Dr. Turk and Dr. Budson will confirm all mild AD dementia diagnoses

For Mild cognitive impairment (MCI)

  • meets MCI due to AD NIA-AA criteria
  • MMSE > 23
  • performance on delayed recall and recognition memory worse than 1.0 SD for age \& education adjusted norms
  • Dr. Turk and Dr. Budson will confirm all MCI due to AD diagnoses

Exclusion criteria

Exclusion Criteria:

A clinically significant problem of any of the following conditions:

  • depression
  • heavy alcohol or drug use
  • cerebrovascular disease
  • traumatic brain damage
  • a different degenerative disease (e.g., fronto-temporal dementia, Parkinson's disease)
  • any medical condition whose severity could significantly impair cognition (e.g., organ failure)
  • Unable to understand the consent form
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Group 1- 15 Mild AD and 15 MCI due to AD

    In Group 1, for the first 2 weeks participants will be taught memory strategies and reminded to use them each day from week 0 to week 2. Weeks 3-4, participants will be advised to keep using the strategies both on the tablet and in their daily life even though they will not be reminded each time they start the task.

    Behavioral: Memory strategies in Arm 1 · Device: Electroencephalogram (EEG) headset in Arm 1 · Other: Tablet in Arm 1

  • Active comparator
    Group 2- 15 Mild AD and 15 MCI due to AD

    In Group 2, for the first 2 weeks participants will be reminded to "try hard" to remember the items although they will not be given any specific strategies. At week 2 the subjects will be taught memory strategies and reminded to use them each day from week 2 to week 4.

    Behavioral: Memory strategies in Arm 2 · Device: Electroencephalogram (EEG) headset in Arm 2 · Other: Tablet in Arm 2

Interventions

  • BehavioralMemory strategies in Arm 1

    Memory strategies will consist of daily at-home exercises lasting between 20 minutes to 1 hour depending on the memory tasks assigned to each participant. At the start of week 1 participants will be taught the memory strategies to use while completing the daily memory tasks. In week 1 and 2, subjects will be reminded daily to use the memory strategies. At the start of week 3, subjects will be advised to use the memory strategies however they will not be given daily reminders.

  • DeviceElectroencephalogram (EEG) headset in Arm 1

    A cap that measures brain activity using a 16-sensor wireless dry (no gel applied) EEG device designed by BrainWaveBank Ltd., that uses Bluetooth technology to securely transmit EEG signals to an Android tablet. The cap will be used during week 1,2,3 and 4.

  • OtherTablet in Arm 1

    A computer tablet will be provided to each participant that will have daily reminders about the memory strategies during week 1 and 2, while no reminders will be present in week 3 and 4. The tablet software includes a user-friendly interface that provides feedback and instructions that help the participant properly wear the EEG headset. At the end of each session the tablet stores behavioral and EEG data on a secured server accessible by the research staff.

  • BehavioralMemory strategies in Arm 2

    Memory strategies will consist of daily at home exercises lasting between 20 minutes to 1 hour depending on the memory tasks assigned to each participant. During weeks 1 and 2, participants will be completing the memory tasks without being instructed to use any specific strategy. At the end of week 2 subjects will be taught the memory strategies and during week 3 and 4, they will be reminded daily to use the memory strategies while completing the memory tasks.

  • DeviceElectroencephalogram (EEG) headset in Arm 2

    A cap that measures brain activity using a 16-sensor wireless dry (no gel applied) EEG device designed by BrainWaveBank Ltd., that uses Bluetooth technology to securely transmit EEG signals to an Android tablet. The cap will be used during week 1,2,3 and 4.

  • OtherTablet in Arm 2

    A computer tablet will be provided to each participant. During week 3 and 4, the tablet will present daily reminders to use memory strategies while completing the memory tasks. The tablet software includes a user-friendly interface that provides feedback and instructions that help the participant properly wear the EEG headset. At the end of each session the tablet stores behavioral and EEG data on a secured server accessible by the research staff.

06

What researchers measure

Primary outcomes

  1. Change in performance in memory tasks over time

    Change in performance in memory tasks will be measured through daily at home memory exercises that will last from 20 minutes to 1 hour. Higher the scores on the exercise represent better memory performance.

    Time frame: baseline, 4 weeks

Secondary outcomes

  1. Change in electroencephalogram (EEG) early negative frontal component (N400)

    Change in EEG early negative frontal component (N400) will be assessed by measuring amplitude and latency characteristics of this EEG component. A higher amplitude and shorter latency will show improvement in memory performance.

    Time frame: Baseline, 4 weeks

  2. Change in EEG Late Positive Parietal Component (LPC)

    Change in EEG Late Positive Parietal Component (LPC) will be assessed by measuring amplitude and latency characteristics of this EEG component. A higher amplitude and shorter latency will show improvement in memory performance.

    Time frame: Baseline, 4 weeks

  3. Change in EEG Late Positive Frontal Effect (LFE)

    Change in EEG Late Positive Frontal Effect (LFE) will be assessed by measuring the amplitude and latency characteristics of this EEG component. A higher amplitude and shorter latency will show improvement in memory performance.

    Time frame: Baseline, 4 weeks

  4. Neuropsychological assessment using the Montreal Cognitive Assessment (MoCA)

    Neuropsychological assessment will be completed using the Montreal Cognitive Assessment (MoCA). The MoCA has a total score of 30, and a higher score means improved cognitive performance.

    Time frame: baseline, 4 weeks

  5. Neuropsychological assessment using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).

    Neuropsychological assessment will be completed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). The RBANS has a total index score of 160, and it measures performance in the following domains: immediate memory, visuospatial, language, attention, and delayed memory. A higher score on the RBANS means improved cognitive performance.

    Time frame: Baseline, 4 weeks

  6. Generalization of strategies to daily life functioning

    Generalization of strategies will be assessed through the Activities of Daily Living Scale (ADL) which is a 31-item questionnaire assessing the ability to complete activities of daily living. The minimum score is 0 while the maximum score is 279. A lower score on the Activities of Daily life scale means a greater level of independence in completing activities of daily life.

    Time frame: Baseline, 4 weeks

  7. Quality of life with Alzheimer's disease

    Quality of life will be assessed with the Quality of Life in Alzheimer's Disease (QoLAD) which is a 13-item questionnaire assessing different aspects of quality of life. The minimum score is 13 and the maximum is 52. A higher score represents better quality of life.

    Time frame: Baseline, 4 weeks

  8. Subjective perception of memory performance

    Subjective perception of memory performance will be assessed using the Multifactorial Metamemory Questionnaire (MMQ), which is a 61-item questionnaire divided in three subcategories (Contentment, Ability and Strategy). The minimum score is 0 and the maximum is 244. A higher score means a better subjective memory performance.

    Time frame: Baseline, 4 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04942184
Lead sponsor
Boston University
Collaborators
National Institute on Aging (NIA)
Responsible party
Sponsor
First posted
Jun 28, 2021
Start date
Oct 2022 (estimated)
Primary completion
Jun 2023 (estimated)
Completion
Jun 2023 (estimated)
Last update
Nov 1, 2022

Study contacts

Katherine Turk, MD
principal investigator · BU School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion